Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
1(20.0%)
N/A
1(20.0%)
5Total
Phase 2(3)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01876862Not ApplicableCompleted

Towards HIV Functional Cure

Role: lead

NCT00976404Phase 2Completed

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

Role: collaborator

NCT01019551Phase 2Completed

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients

Role: lead

NCT01019044Completed

Exploration of HIV Reservoirs

Role: lead

NCT00219362Phase 2Completed

Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

Role: lead

NCT00261001Phase 1Completed

Safety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular Route

Role: lead

All 6 trials loaded